About Funxional Therapeutics
FXT is focusing on novel anti-inflammatory therapies and intends to advance its proprietary drug candidates up to the clinical proof of concept, then seeking partnerships for further development of the products.
The most advanced compound in FXT’s product portfolio is FX125L, which completed the single and multiple dose Phase I clinical trials in January 2010 in the USA. FX125L is an orally available small molecule which belongs to the new class of Broad Spectrum Chemokine Inhibitors (BSCIs). BSCIs are anti-inflammatory compounds with a novel mechanism of action that involves the selective interaction with a single well-characterized receptor resulting in potent inhibition of inflammatory cell migration in response to chemokines. Other BSCIs have also been identified as back up molecules and as candidates for development as topical anti-inflammatory agents.
Work is continuing to identify a lead compound in a novel class of small molecules that can stimulate the clearance of cell debris (Apolipoprotein-E mimetics), with applications in inflammation but also in other disease areas. Further development in our third proprietary technology, the G-protein coupled receptors Agonist-Enriched Libraries (GAEL), will be achieved through licensing-out of this technology to a suitable partner.
FXT commenced operations in January 2007 and is managed by a very experienced team, backed by funding from Index Ventures and Novo A/S, while its shareholders also include Ipsen and Cambridge University.
FXT’s research facilities are based in Cambridge (UK), while the development work is managed centrally but conducted internationally through Contract Research Organizations and a network of expert advisors in each operational area.